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Background: The phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is commonly deregulated
in human cancer, hence many PI3K and mTOR inhibitors have been developed and have now reached clinical trials. Similarly,
CDKs have been investigated as cancer drug targets.
Methods: We have synthesised and characterised a series of 6-aminopyrimidines identified from a kinase screen that inhibit PI3K
and/or mTOR and/or CDK2. Kinase inhibition, tumour cell growth, cell cycle distribution, cytotoxicity and signalling experiments
were undertaken in HCT116 and HT29 colorectal cancer cell lines, and in vivo HT29 efficacy studies.
Results: 2,6-Diaminopyrimidines with an O4-cyclohexylmethyl substituent and a C-5-nitroso or cyano group (1,2,5) induced cell
cycle phase alterations and were growth inhibitory (GI50o20 mM). Compound 1, but not 2 or 5, potently inhibits CDK2 (IC50¼ 0.1
nM) as well as PI3K, and was cytotoxic at growth inhibitory concentrations. Consistent with kinase inhibition data, compound 1
reduced phospho-Rb and phospho-rS6 at GI50 concentrations. Combination of NU6102 (CDK2 inhibitor) and pictilisib (GDC-0941;
pan-PI3K inhibitor) resulted in synergistic growth inhibition, and enhanced cytotoxicity in HT29 cells in vitro and HT29 tumour
growth inhibition in vivo.
Conclusions: These studies identified a novel series of mixed CDK2/PI3K inhibitors and demonstrate that dual targeting of CDK2
and PI3K can result in enhanced antitumour activity.
Insights into the molecular pathology of cancer have resulted in the
development of targeted approaches for cancer therapy. The
phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/
mTOR) pathway is one of the most commonly deregulated pathways in
human cancer in which signals are transduced via a cascade of lipid and
serine/threonine kinases resulting in diverse effects on proliferation,
apoptosis, protein translation, DNA repair, survival and transformation
(for review see (Mayer and Arteaga, 2015)). Activation of receptor
tyrosine kinases (RTKs) stimulates the PI3K pathway via adapter
proteins, and PI3K phosphorylates phosphoinositide-3,4-biphosphate
(PIP2) to generate PIP3 that activates AKT(PKB). AKT has many
functions including roles in cell migration, apoptosis and glucose
uptake, and the activation of mTOR via downregulation of the TSC1/
Rheb complex. mTOR in a complex with Raptor (to form mTORC1)
signals via p70S6 kinase and 4EBP1 to regulate the translation of
proteins and cell growth. mTOR also complexes with Rictor (to form
mTORC2) to activate AKT. Negative feedback occurs at many nodes in
the PI3K/mTOR cascade, most notably by PTEN and by S6 kinase-
mediated regulation of RTK signalling, for example, by downregulation
of IRS-1 (Harrington et al, 2005).
*Correspondence: Dr C Cano; E-mail: celine.cano@ncl.ac.uk
{Deceased.
Revised 31 May 2016; accepted 14 July 2016; published online 16 August 2016
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
FULL PAPER
Keywords: CDK2; PI3K; combination; colorectal; cancer; synergy
British Journal of Cancer (2016) 115, 682–690 | doi: 10.1038/bjc.2016.238
682 www.bjcancer.com |DOI:10.1038/bjc.2016.238
Activating mutations in the PIK3CA (p110a) isoform of PI3
kinase are observed in a wide range of tumours including breast,
colon, glioblastoma and ovarian cancers (Cancer Genome Atlas
Research Network, 2008; Stemke-Hale et al, 2008; Mayer and
Arteaga, 2015), and inactivation of the tumour suppressor protein
PTEN has been documented in, among others, glioblastoma, breast
cancer, prostate cancer and melanoma (Cairns et al, 1997; Garcia
et al, 1999; Celebi et al, 2000; Cancer Genome Atlas Research
Network, 2008). More rarely AKT mutations or amplifications
have been detected in colorectal, head and neck, pancreatic and
breast tumours, and large a proportion of cancers have activation
of mTORC1 as demonstrated by increased phosphorylation of
proteins such as S6 kinase, 4EBP1, ribosomal S6 protein and
mTOR itself (reviewed in (Menon and Manning, 2008)).
Considerable effort has been focussed on the development of
PI3K/mTOR pathway inhibitors, many of which have now reached
clinical trials (Yap et al, 2015). Rapamycin, discovered as an
antifungal agent from Streptomyces hygroscopicus, was the first
mTOR inhibitor characterised and a number of the trial candidates
are rapamycin analogues (rapalogues). Rapamycin binds to FK-
binding protein 12 and therefore only inhibits the mTORC1
complex and not mTORC2. Rapamycin has been approved for the
treatment of advanced renal cell carcinoma and, following
promising Phase III trials, the rapalogues temsirolimus and
everolimus have been approved for renal cell carcinoma and soft
tissue/bone sarcomas, respectively (Chiarini et al, 2015). In
addition, compounds are in clinical trials that block both mTORC1
and mTORC2 by competitive inhibition at the ATP-binding site
(Chiarini et al, 2015).
ATP competitive inhibitors of PI3 kinase have also entered
clinical trials (Chiarini et al, 2015). These compounds mainly target
the p110a isoform of PI3K, but some have been developed that have
selectivity for other isoforms, for example, idelalisib inhibits p110d
but not a or b (Lannutti et al, 2011). Compounds such as dactolisib
target PI3K and mTOR at similar potency, and others such as
pictilisib are pan-PI3K inhibitors (Brachmann et al, 2009). A review
of published early clinical trial data indicates that PI3K inhibitors are
well tolerated and as single agents they can induce disease
stabilisation, and in some cases regression (Brachmann et al, 2009;
Engelman, 2009). Preclinical data suggest that combinations of PI3K
inhibitors with other targeted therapies, for example, MEK
inhibitors (Engelman et al, 2008; Haagensen et al, 2012;
Haagensen et al, 2013), can result in significant synergism and
clinical trials to explore such combinations are ongoing.
Cyclin-dependent kinases (CDKs) regulate cell cycle progression
and transcription via sequential interaction with specific cyclins. In
some cancers defects in the expression of CDKs and their
regulatory proteins, for example, loss of CDK inhibitors or
upregulation of cyclin expression, leads to aberrant regulation of
the cell cycle (Satyanarayana and Kaldis, 2009). CDK2 has an
important role in the G1 to S-phase transition and also has a role
in S-phase progression. In particular, phosphorylation of Retino-
blastoma protein (Rb) by cyclin D/CDK4 and 6 complexes,
followed by the cyclin E/CDK2 complex, inactivates Rb releasing
E2F and thereby promoting S-phase entry and progression
(Harbour et al, 1999; Aleem et al, 2004). Numerous small molecule
inhibitors of CDKs have been evaluated in clinical trials (Shapiro,
2006; Asghar et al, 2015), some of which are pan-CDK inhibitors
such as flavopiridol, whereas other compounds are more selective.
Preliminary clinical data with CDK inhibitors suggests they are
generally well tolerated but rarely induce marked anti-proliferative
toxicity or tumour regressions when given as single agents
(Shapiro, 2006; Asghar et al, 2015). Thus, with the exception of
flavopiridol for the treatment of chronic lymphocytic leukaemia
(Lin et al, 2009), where the transcriptional kinase CDK9 is thought
to be the primary target, and palbociclib for the management of
ER-positive HER2-negative breast cancer, where CDK4/6 is the
target (Rocca et al, 2014), it has yet to be determined whether
CDK-specific or pan-CDK inhibitors are preferable (Shapiro,
2006), or indeed if this compound class generally possesses
widespread antitumour activity.
In a counter-screen of compounds designed to inhibit CDK2 we
identified a number of molecules that were also mTOR and/or PI3
kinase inhibitors. These compounds provided an opportunity to
evaluate the impact of simultaneous modulation of cell cycle and
survival/growth signalling, via dual CDK and PI3K/mTOR
inhibition, which revealed that potent CDK2 inhibition combined
with PI3K inhibition resulted in cell cycle and growth inhibition,
and cytotoxicity. In vitro results with a dual CDK/PI3K inhibitor
were recapitulated using a combination of a selective CDK2
inhibitor (NU6102) and a pan-PI3K inhibitor (pictilisib), and
extended to in vivo studies that showed enhanced tumour growth
inhibition with the drug combination.
MATERIALS AND METHODS
Materials. Dactolisib and pictilisib were purchased from Stratech
Scientific (Suffolk, UK) and rapamycin from Merck (Nottingham,
UK). Anti phospho-4EBP1 (Cat# 2855S), 4EBP1 (Cat# 9644),
phospho-AKT (Cat# 4060S), AKT (Cat# 4691S), phospho-
ribosomal S6 (Cat# 4858S) and ribosomal S6 (Cat# 2217S)
antibodies were purchased from NEB (Hitchin, UK). Anti
phospho-Rb (Cat# 44–582G) was supplied by Invitrogen (Paisley,
UK) and anti-Rb (Cat# 554136) by BD Biosciences (Oxford, UK).
All other reagents were analytical grade where available and
supplied by Sigma (Gillingham, UK).
Synthesis of compounds. The following compounds were synthe-
sised as previously described: 1 (Sayle et al, 2003), 2 (Arris et al,
2000), 3 and 4 (Mesguiche et al, 2003), 5 and 6 (Marchetti et al,
2010). 7 and 8 were synthesised as described in Supplementary
Material. NU6102 (4-[[6-(cyclohexylmethoxy)-9H-purin-2-yl]a-
mino]-benzenesulfonamide) was synthesised as previously
described (Davies et al, 2002).
Enzyme assays. PI3Ks (Condliffe et al, 2005) and CDK2 (Arris
et al, 2000) assays were performed as previously described.
The inhibition of mTOR kinase activity at 10 mM ATP was
measured by TR-FRET according to the manufacturer’s
instructions (http://tools.invitrogen.com/Content/SFS/lanthascreen/
PV4753%20FRAP1%20Assay%20Validation.pdf).
Cell culture. HCT116 and HT29 cells were obtained from ATCC
(Teddington, UK), and grown in DMEM supplemented with 10%
(v/v) fetal bovine serum, 100 unitsml 1 penicillin, 0.1mgml 1
streptomycin and 2mM L-glutamine.
Cell growth inhibition assays. Cells were trypsinised and plated
in 96-well plates at a seeding density of 1000 cells per well. Twenty-
four hours later cells were incubated for 72 h with 0.001–100 mM of
each inhibitor dissolved in DMSO with a final DMSO concentra-
tion of 1% (v/v). Cells were fixed with 50% (w/v) TCA and stained
with 0.4% (w/v) sulforhodamine B (SRB) for 30min before
washing with 1% (v/v) acetic acid. SRB was solubilised with 10mM
Tris pH 10.5, the absorbance read at 570 nM, and cell growth
expressed as % of the growth of cells exposed to 1% (v/v) DMSO.
The concentration of compound that resulted in 50% growth
inhibition (GI50) was calculated by interpolation from the growth
inhibition/concentration curves using GraphPad Prism software
(La Jolla, USA). Combination growth inhibition studies of NU6102
and pictilisib were performed as previously described (Haagensen
et al, 2012).
Clonogenic assays. Cells were seeded in six-well plates at a density
of 1 105 per well and allowed to adhere overnight. The GI50
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concentration from the SRB assay for the pyrimidine compounds
1–8 was added to the cells for 8 or 72 h. Cells were washed twice
with PBS before the addition of standard growth medium.
Following incubation to allow colony (450 cells) formation, cells
were fixed with Carnoy’s solution and stained with 0.4% (w/v)
crystal violet solution for 1 h. Colonies were washed with 1% (v/v)
acetic acid and counted using an Oxford Optronix Colcount
(Oxford, UK). Single agent and combination cytotoxicity studies
with NU6102 and pictilisib at 1 or 10 mM were performed using the
same method with cells being exposed to drugs for 72 h before
plating out for colony formation. Statistical analyses were
performed using ANOVA.
Flow cytometry. Cells were seeded in six-well plates at a density of
4 105 per well and allowed to adhere overnight. Incubation of the
cells with the GI50 concentration of each compound for up to 24 h,
was followed by washing with PBS and cell removal with trypsin.
Trypsinised cells were centrifuged, washed with PBS and fixed with
75% ethanol/25% PBS (v/v) overnight. Pellets were rehydrated with
PBS and stained using 1mgml-1 RNase and 400mgml 1
propidium iodide for 4 h, and analysed using a Becton Dickinson
FACSscan and Cellquest software (BD biosciences) with data
evaluation using WinMdi software (http://facs.scripps.edu/
software.html) and ANOVA statistical analysis.
Western blotting. Cells were seeded in six-well plates at a density
of 4 105 per well and allowed to adhere overnight. Cells were
incubated with 0.5, 5 or 50 mM 1 or 5 for 4, 8 or 24 h before being
washed and extracted with Phosphosafe buffer (Merck). Protein
concentrations were determined by bicinchoninic acid assay
(Thermo Scientific, Cramlington, UK) and 30 mg of total protein
for each sample was loaded into the wells of a 4–20% tris-glycine
Novex gel (Invitrogen). Proteins were resolved at 120V for B2 h
before being transferred to Hybond-C nitrocellulose (GE Health-
care, Chalfont St Giles, UK). Membranes were probed with the
appropriate dilution of antibody overnight and, after washing, the
appropriate secondary antibody used at a dilution of 1 : 1000,
followed by analysis using Supersignal West Dura enhanced
chemiluminescence substrate (Thermo Scientific).
In vivo studies. All of the in vivo experiments were reviewed and
approved by the institutional animal welfare committee, and
performed according to the United Kingdom Coordinating
Committee on Cancer Research (UKCCCR) Guidelines for the
Welfare of Animals in Experimental Neoplasia (second edition)
and national law. CD-1 nude mice (Charles River, Ramsgate, Kent,
UK) were implanted with 1 107 HT29 cells, in a mixture of
Matrigel/RPMI cell culture media (1 : 1 v/v), subcutaneously on the
right flank. Tumours were allowed to develop until they were
palpable (B0.5 0.5 cm, 10–12 days after implantation) and
randomised into four treatment groups (six animals per group).
Mice were treated with vehicle (control), NU6301 120mg kg 1 i.p.
(a water soluble prodrug of NU6102 (Thomas et al, 2011);
120mg /kg 1 NU6301 being equivalent to 100mg kg 1 NU6102)
twice daily, 100mg kg 1 pictilisib p.o. once daily, or the
combination of twice daily NU6301 (120mg kg 1 i.p.) and once
daily pictilisib (100mg kg 1 p.o.) for 10 days. Tumour volume was
calculated from two-dimensional calliper measurements using the
equation a2 b/2, where a is the smallest measurement and b the
largest. Data are presented as median relative tumour volumes
(RTV), where the tumour volume on the initial day of treatment
(day 0) is assigned an RTV value of 1 in accordance with the
formula: RTV¼ tumour volume on day of observation/tumour
volume on day 0. Statistical analyses of the effects of drug
treatment was undertaken using the Mann–Whitney test.
RESULTS
The structures of the compounds tested are shown in
Supplementary Figure 1 and their activity as inhibitors of CDK2,
the four PI3K isoforms and mTOR in purified kinase assays is
shown in Table 1; ranked in order of potency as inhibitors of
CDK2. Sulphonamide 1 is an extremely potent inhibitor of CDK2
(IC50 0.1 nM) and a low mM inhibitor of all of the PI3K isoforms
with the exception of PI3Kb. However, 1 did not inhibit mTOR at
the highest concentration tested (20 mM). The parent compound in
this series, 2, inhibited CDK2 and all of the PI3K isoforms at
similar concentrations (1–10 mM), but was somewhat less potent
against mTOR. The cyano compound 7 has IC50 values in the
range 10–20 mM for CDK2 and the PI3Ka, d and g isozymes, but
like 1 is less active against PI3Kb and mTOR. The nitroso
compound 6 is similar to 7, although somewhat less active against
CDK2 and more active against PI3Ks a, d and g. The aldehyde 4
and cyano compound 5 are similar to 6, although 4 is distinct in
having an IC50 for mTOR of 15 mM, vso5% inhibition for 6 and 5
at 20 mM. Also, 5 is less active than 6 and 4 against CDK2.
Importantly, the O4-(4-chlorobenzyl) compound 8 did not inhibit
CDK2 but is an inhibitor of all four PI3K isozymes and mTOR,
whereas 3 is only active against mTOR (IC50 13 mM).
The cell growth inhibitory activity of each compound was tested
using the SRB assay in HCT116 and HT29 cells. GI50 values were
calculated from the mean of three separate assays for each
compound, and are given in Table 2. Rapamycin, dactolisib (NVP-
BEZ235), pictilisib (GDC-0941; pictrelisib) and NU6102 were used
as positive controls for mTOR inhibition, dual PI3K and mTOR
inhibition, pan-PI3K inhibition and CDK2 inhibition, respectively.
Compounds 1, 2 and 5 were equipotent in both cell lines, similar in
potency to rapamycin, but markedly less potent than the dual
PI3K/mTOR inhibitor dactolisib. Inhibitors 4, 7 and 8 also had
similar GI50 values, but were 5–10-fold less potent at inhibiting cell
Table 1. Inhibition of CDK2, PI3K and mTOR kinases by 6-aminopyrimidines
Compound CDK2 PI3Ka PI3kb PI3Kd PI3Kc mTOR
1 0.0001±0.00003 3.6, 6.2 420 3.2, 7.5 3.7, 6.8 420
2 2.2±0.5 1.3, 2.7 5.7, 11 0.7 , 1.8 1.5, 2.1 19
7 9.6, 13 9.9, 12 420 12, 14 18, 20 420
6 7.5, 22 2.9, 4.4 420 5.0, 6.5 2.9, 7.1 420
4 22, 24 5.4, 11 420 2.9, 5.6 1.7, 5.3 15
5 60±10 4.5, 7.7 18, 23 6.9, 5.9 7.5, 12 420
8 4410 2.5, 6.2 4.3, 13 0.5, 1.1 1.5, 2.0 4.9
3 4410 420 420 420 420 13
Abbreviations: mTOR¼mammalian target of rapamycin; PI3K¼phosphatidylinositol-3-kinase. Values are the IC50 (mM) or the highest concentration tested (mM), and are the mean±s.d. or
individual determinations. For chemical structures see Supplementary Figure 1.
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growth than 1, 2 and 5. Growth inhibition induced by 3 and 6 did
not reach 50% at 100 mM, inducing a maximum of 35% reduction in
growth at 100 mM in HCT116 cells.
The effects of the compounds on cell cycle phase distribution at
GI50 concentrations, or at 100 mM for 6 and 3, in asynchronous
cultures were evaluated by flow cytometry in HCT116 cells
(Figure 1A). An increase in the G1 population was observed, of
varying magnitude, with 2, 4 and 5 producing greater G1 phase
accumulation than rapamycin or dactolisib (NVP-BEZ235). No
effect on cell cycle phase distribution was observed with 100 mM 3.
Compound 1 was unique in inducing the formation of a sub-G1
fraction, indicative of apoptosis (Figure 1). Further analysis of the
effect of 1 on the cell cycle indicated that the sub-G1 fraction
became apparent from 3 h onwards in HCT116 cells (Figure 1B).
The increase in the sub-G1 fraction was significant after 3 h
(P¼ 0.013) and remained significant up to 8 h (Po0.002). The G1
fraction was reduced after 4 h exposure to 1, but was only
significant at the 10% level (Po0.09), whereas the S-phase fraction
was significantly reduced at 4 h (Po0.016). The increase in the G2/
M phase fraction was significant at both 4 and 6 h (Po0.011). In
HT29 cells, 1 induced a time-dependent increase in the G2/M
fraction, with a sub-G1 fraction becoming apparent from 6 h
onwards (Figure 1C), which was concentration-dependent at 24 h
(Supplementary Figure 2). Although a sub-G1 fraction was
apparent at 6 and 8 h, this was not significant (P¼ 0.183 at 8 h);
whereas the G1 fraction was significantly reduced after 4 h
(Po0.002). The S-phase fraction in HT29 cells was significantly
reduced after 6 h (Po0.04) treatment with 1, and the G2/M
fraction was significantly increased after 4 h (Po0.002).
To determine whether the sub-G1 fraction observed following
treatment with 1 reflected cytotoxicity, clonogenic survival assays
were performed in HCT116 and HT29 cells following an 8 h
exposure. Compound 1 reduced the clonogenic survival of cells in
a concentration-dependent manner in both HCT116 and HT29
cells (Figure 2A and B), with 50% inhibition of colony formation at
5 mM. Consistent with the lack of a sub-G1 peak in flow cytometry
experiments, the other pyrimidine inhibitors were not cytotoxic in
either cell line even after 72 h exposure (HCT116 cells; Figure 2C).
To explore the contribution of CDK2 inhibition to the
cytotoxicity of 1, the effects of 1 and 5 on target protein
phosphorylation were examined in HCT116 (Figure 3) and
HT29 (Supplementary Figure 3) cells following 4, 8 and 24 h
exposure. Compound 5 was selected as being equipotent to 1
against PI3Ks and mTOR, with similar growth inhibitory potency
in both cell lines but 600 000-fold less active against CDK2
Table 2. Colorectal tumour cell growth inhibition by 6-
aminopyrimidines
Compound GI50 HCT116 (lM) GI50 HT29 (lM)
1 4.3±2.6 12±3
2 6.2±1.8 12±4
7 73±28 4100mM (30%)
6 4100mM (35%) 4100mM (1%)
4 64±18 44±5
5 6.7±1.8 14±6
8 52±11 59±20
3 4100mM (30%) 4100mM (17%)
Dactolisib (NVP-BEZ235) 0.016±0.008 0.014±0.001
Rapamycin 2.3±1.5 4.2±1.4
NU6102 5.7±0.4 13.3±3.4
Pictilisib (GDC-0941) 1.7±0.3 0.25±0.13
Values are the mean GI50±s.d., or the highest concentration tested and the % growth
inhibition observed at that concentration.
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Figure 1. Cell cycle phase analysis following exposure to 6-aminopyrimidine inhibitors measured by flow cytometry. (A) HCT116 cells were
treated with GI50 concentrations of inhibitors (or 100mM, Table 2) for 24 h then fixed, stained with propidium iodide and analysed by flow
cytometry. Cell cycle phase distribution was analysed by WinMDI software, and the mean cell cycle fraction of cells gated into each phase of the
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(Tables 1 and 2). Compound 1 induced concentration-dependent
inhibition of Rb phosphorylation in HCT116 cells, with inhibition
at a GI50 concentration of 5 mM being observed at all time points,
and at 24 h in HT29 cells. In contrast, the effect of 5 on Rb
phosphorylation was less pronounced and only clearly observed
after 24 h exposure to 50 mM. Compounds 1 and 5 had similar
effects on rS6 phosphorylation in both cell lines, and only 5
consistently reduced AKT phosphorylation at 50 mM.
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The results obtained with compound 1 in comparison with the
other compounds suggested that dual CDK2 and PI3K inhibition
resulted in cytotoxicity, and to confirm this suggestion studies were
performed with the potent CDK2 inhibitor NU6102 (4-[[6-
(cyclohexylmethoxy)-9H-purin-2-yl]amino]-benzenesulfonamide)
(Davies et al, 2002) in combination with the pan-PI3K inhibitor
pictilisib. As shown in Figure 4A, the combination of NU6102 and
pictilisib was synergistic in growth inhibition studies in both the
HCT116 and HT29 cell lines. Furthermore, the combination of the
two drugs at 10 mM was cytotoxic to HT29 cells, which was
significantly enhanced compared with either compound alone at
this concentration (Figure 4B; Pp0.0001). However, in the
HCT116 cell line, there was only a significant increase in
cytotoxicity with the combination compared to pictilisib alone
(Pp0.0001), as NU6102 was cytotoxic as a single agent
(Figure 4B).
An in vivo tumour growth inhibition study was performed using
the HT29 model treated for 10 days with the NU6102 prodrug
NU6301 at 120mg kg 1 twice each day (equivalent to
100mg kg 1 NU6102), pictilisib (GDC-0941) at 100mg kg 1
per day or the combination of the two drugs at these doses, which
were based on in vivo pharmacodynamic data from earlier studies
(Thomas et al, 2011; Haagensen et al, 2013). Compound 1 was not
suitable for in vivo studies as it contains a 5-nitroso group, which is
notoriously metabolically labile and potentially reactive. As shown
in Figure 4C, RTV in mice treated with the combination of
NU6301 and pictilisib (GDC-0941) were significantly lower in
comparison with either of the drugs alone (P¼ 0.008 and
P¼ 0.018, respectively, Mann–Whitney test) at the end of
treatment (day 10). There was no tumour growth in the
combination group while on treatment, whereas single-agent
treatment at the doses used only generated growth delays, which
were not significant in the case of NU6301 alone (time to RTV4 vs
control – P¼ 0.13, Mann–Whitney test), and not highly significant
in the case of pictilisib (GDC-0941; time to RTV4 vs control –
P¼ 0.026, Mann–Whitney test). In contrast, growth delay was
highly significant for the combination therapy (time to RTV4 vs
control – P¼ 0.0043, Mann–Whitney test). Although a formal
toxicology study was not performed, the combination treatment
was well tolerated with no consistent impact of single-agent
or combination drug treatment on body weights or clinical
condition.
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Figure 4. The impact of combined CDK2 and PI3K inhibition on colorectal tumour cell growth and survival in vitro, and HT29 tumour growth
in vivo. (A) HCT116 or HT29 cells were exposed to combinations of NU6102 and pictilisib at fixed ratios (0.25 , 0.5 , 1 , 2 and 4 ) of their
respective GI50 concentrations (NU6102: HCT116 5.7mM, HT29 13mM; pictilisib: HCT116 1.7mM, HT29 0.25mM) and cell growth inhibition evaluated by
median effect analysis. (B) Cytotoxicity of 1mM or 10mM NU6102 and pictilisib alone and in combination in HCT116 and HT29 colorectal tumour cell lines.
(C) Efficacy of the NU6102 prodrug NU6301 and pictilisib, alone and in combination, in HT29 human colorectal tumour xenograft bearing mice. Mice
were treated with vehicle (control), NU6301 120mgkg 1 i.p. (equivalent to 100mgkg 1 NU6102) twice daily, 100mgkg 1 pictilisib p.o. once daily, or
the combination of twice daily NU6301 (120mgkg1 i.p.) and once daily pictilisib (100mgkg 1 p.o.) for 10 days. Data are the relative tumour volume
(RTV) at the end of treatment (day 10) and P-values are the statistical differences between the groups as indicated by the Mann–Whitney test.
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DISCUSSION
Inhibitors of mTOR, PI3K and CDK2 are currently in various
stages of clinical development. Extensive preclinical studies
indicate that combinations of targeted agents may demonstrate
greater antitumour activity and selectivity than single agents, the
combination of PI3K and MEK inhibitors being an excellent
example (Engelman et al, 2008; Haagensen et al, 2012; Haagensen
et al, 2013). Counter-screening of compounds synthesised to target
CDK2 identified a number of pyrimidines that were able to inhibit
PI3K and/or mTOR, and we evaluated inhibitors with a range of
potencies against CDK2, PI3K and mTOR for their effects on cell
growth, cell cycle phase distribution and cytotoxicity.
In the two colorectal cancer cell lines studied, HCT116 and
HT29, three of the compounds had GI50 values of o20 mM: 1, 2
and 5. The wide range of potencies of these compounds as
inhibitors of CDK2 (0.1, 2200 and 60 000 nM, respectively) and the
lack of activity against mTOR of two of the compounds (o5%
inhibition at 20 mM: 1 and 5), yet similar potency for PI3K
inhibition, is not inconsistent with growth inhibition owing to
activity against the latter targets. The reduced growth inhibitory
properties on 4, 6, 7 and 8, despite similar potency against PI3Ks to
1, 2 and 5, may be due to reduced cellular uptake resulting from
the major structural changes at the 4-position (replacement of the
cyclohexylmethyl group in 6, 7, 8) or 5-position (replacement of
the nitroso group with formyl in 4). In this latter regard, removal
of the 5-nitroso group (3) resulted in complete loss of activity
against CDK2 and PI3Ks; however, interestingly, modest mTOR
inhibition was retained. Nevertheless, despite the mTOR inhibitory
activity of 3, the compound did not inhibit cell growth. The reason
for the lack of CDK2 inhibition by 3 can be explained by the
absence of an intra-molecular hydrogen bond as in 1 (i.e., between
the 5-nitroso and the 6-amino group), which is critical for
maintaining the correct orientation of the 6-amino group for
hydrogen bonding to Glu-81 of CDK2 (Arris et al, 2000). A similar
effect may explain the lack of activity of 3 against PI3Ks, although
there are no structural data to support this contention.
When asynchronous cell cultures were treated with GI50
concentrations of the growth inhibitory compounds the predomi-
nant effect was an accumulation of cells in the G1 phase of the cell
cycle. Both rapamycin and dactolisib (NVP-BEZ235) also caused a
G1 arrest at their GI50 concentrations, an effect that has been
previously reported with PI3K and/or mTOR inhibitors (Mita et al,
2003; Serra et al, 2008). In contrast to the other growth inhibitory
compounds, 1 initially either had no effect on the fraction of cells
in the G1 phase (HCT116) or reduced the size of the G1 fraction
(HT29), before rapidly (p6 h) inducing a sub-G1 population in
both cell lines indicative of apoptosis, although only significantly in
the HCT116 cells. The impact of the apoptosis induced by 1 was
revealed by clonogenic cytotoxicity studies where the compound
was shown to be cytotoxic to both HCT116 and HT29 cells
following exposure for 8 h at growth inhibitory concentrations. In
marked contrast, exposure of HCT116 cells for 72 h to all of the
other pyrimidines failed to induce significant cytotoxicity.
Together, these cellular data suggest that the potent CDK2
inhibitory activity of 1 contributes to the cytotoxic activity of the
compound.
To evaluate whether the relative potencies of compounds
against purified kinases reflected their activity in a cellular context,
western blotting experiments were performed with 1 and the non-
CDK2 inhibitory control compound, 5. As expected, 1 inhibited
the phosphorylation of the CDK2 substrate Rb at earlier time
points and at lower concentrations than 5, and these data are
consistent with the hypothesis that the apoptosis and cytotoxicity
induced by 1 is related to CDK2 inhibition. Interestingly, despite
good inhibition of rS6 phosphorylation, compound 1 did not
inhibit the phosphorylation of AKT, which is likely to reflect
phosphorylation at this site by other pathways, for example, IKK
has recently been implicated in promoting AKT phosphorylation
at Ser473 (Dan et al, 2016).
To confirm that the cytotoxicity observed with 1 was due to dual
CDK2 and PI3K inhibition, combination studies were performed
with the potent and selective CDK2 inhibitor NU6102 in
combination with the pan-PI3K inhibitor pictilisib. In growth
inhibition studies, a synergistic as opposed to an additive
interaction was observed, particularly in the HCT116 cell line,
and in cytotoxicity studies combination of the two inhibitors was
markedly more cytotoxic in HT29 cells than either compound
alone. Importantly, the superior activity of the combination of the
CDK2 and the PI3K inhibitor was recapitulated in an in vivo
antitumour study without any marked increase in host toxicity, as
evaluated by body weight changes and clinical observations. The
specificity of NU6102 as a CDK2 inhibitor has been well-
established (Davies et al, 2002) and confirmed subsequently in a
study using CDK2 WT and KO MEFs (Thomas et al, 2011). At the
concentrations and doses of NU6102 used in the current study
(10 mM in vitro and 100mg kg 1 in vivo), these previous studies
have demonstrated CDK2 specificity (Davies et al, 2002; Thomas
et al, 2011). Pictilisib is a very widely used and well-characterised
PI3K inhibitor, and was used at doses and concentrations in line
with previous published studies (Haagensen et al, 2012; Haagensen
et al, 2013). Consequently, these tool compounds can be used to
show that dual CDK2 and PI3K inhibition may represent an
approach to improving antitumour selectivity with these two
classes of targeted agents.
Mechanistically, the potential of dual CDK2 and PI3K pathway
inhibition has been highlighted by a number of studies. Initially,
Maddika et al, 2008 demonstrated that nuclear translocation of
AKT results in phosphorylation of CDK2/cyclin A, leading to
cytoplasmic redistribution of CDK2/cyclin A, which was required
for S to G2-M cell cycle phase progression. Subsequently, a
landmark paper (Liu et al, 2014) reported that phosphorylation of
AKT by CDK2/cyclinA2 at S477/T479 was a critical priming event
that precedes AKT activation by phosphorylation at the canonical
S473 locus, and that by this mechanism CDK2/cyclinA1 activity is
a prerequisite for the oncogenic activity of AKT and hence more
generally the PI3K pathway. These recent mechanistic insights
into the interplay between CDK2 and PI3K signalling provide a
rationale for the improved activity of dual CDK2 and PI3K
inhibition described in the current paper. Furthermore, the
effects of the dual pyrimidine-based inhibitor 1 and combined
treatment with the selective CDK2 antagonist NU6102 and the
pan-PI3K inhibitor pictilisib described here are consistent
with the results using alternative small molecule CDK and PI3K
inhibitors, and siRNA (Cheng et al, 2012). In this latter study,
increased apoptosis in vitro and enhanced tumour growth
delay in vivo were observed when both CDK2 and PI3K,
specifically PI3Ka, were modulated by chemical and/or molecular
genetic means.
In summary, we have synthesised and characterised a series of
6-aminopyrimidines identified from a kinase screen that are
inhibitors of PI3K and/or mTOR and/or CDK2. In HCT116 and
HT29 cell lines, PI3K inhibition is associated with cell growth
inhibition, regardless of the activity against CDK2. Likewise, the
level of mTOR inhibition does not influence cell growth inhibitory
potency. Importantly, the mixed CDK2 and PI3K inhibitor 1
induces apoptosis and is cytotoxic, suggesting that dual CDK2/
PI3K targeting may be preferential to inhibition of either enzyme
alone. Mechanistically, the recent identification of direct interac-
tions between CDK2 and AKT, the proximal downstream target of
PI3K signalling, provides a rationale for the simultaneous targeting
of the CDK2 and the PI3K pathway in order to achieve maximal
antitumour effects.
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